Table 1. Patient demographic, clinical and scan-related data.

Patient ID	Age (years)	Weight (kg)	Adm. Activity (MBq)	Gleason Score	PSA level (ng ml^{-1})	Indication	Pretreatments	CTDI$_{vol}$ (mGy)*
P1	70	79	158	4+4	10	PSA-relapse	Local RTx (proton beam)	13.45
P2	73	80	147	4+5	0.3	PSA-relapse	Surgery	12.31
P3	69	113	134	4+3	0.8	PSA-relapse	Surgery + local RTx	18.41
P4	73	77	127	4+4	31	re-staging	ADT, abiraterone, enzalutamide, docetaxel, cabazitaxel, RLT, PSMA-directed bispecific antibodies	11.52
P5	74	77	121	4+5	100	progressive disease	RTx, docetaxel	12.42
P6	64	74	174	3+4	35	primary staging	None	13.10
P7	73	90	110	n/a	0.2	re-staging	Surgery, ADT	14.49
P8	72	80	121	3+3	36	re-staging	None (watch & wait)	11.95
P9	67	118	121	4+5	33	re-staging	ADT, RTx (lumbar spine), docetaxel, [^{223}Ra]RaCl$_2$, RLT	20.15
P10	56	100	163	4+4	12	primary staging	None	18.18
P11	73	83	175	3+4	1.9	PSA-relapse	Surgery + local RTx	12.96
P12	73	106	144	4+4	0.3	PSA-relapse	Surgery	17.48
P13	69	87	143	4+4	1.0	PSA-relapse	Surgery	14.02
P14	82	87	137	n/a	12	PSA-relapse	High intensity focused ultrasound	10.95
P15	81	78	118	3+4	n/a	re-staging	RTx	12.66

* Here, only CTDI$_{vol}$ of the whole-body CT is listed. The CTDI$_{vol}$ related to the CT of the thorax was 6.1 mGy for all patients.

ADT = androgen deprivation therapy; PSMA = prostate specific membrane antigen; RLT = radio ligand therapy (with ^{177}Lu-labelled therapeutic PSMA targeting compounds); RTx = radiation therapy.